Scholar Rock Holding saw the highest growth of 2.99% in patent filings in May and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Scholar Rock Holding’s patent filings and grants. Buy the databook here.
Scholar Rock Holding has been focused on protecting inventions in Australia(AU) with five publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 40% filings and 75% grants. The European Patent Office(EPO), Australia(AU), and United States(US) patent Office are among the top ten patent offices where Scholar Rock Holding is filings its patents. Among the top granted patent authorities, Scholar Rock Holding has 75% of its grants in Australia(AU) and 25% in United States(US).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Scholar Rock Holding
In terms of grant share, Scholar Rock Holding stands in fourth position among its competitors. Regeneron Pharmaceuticals and Amgen secured the top positions according to recent patent publication data.
Patents related to rare diseases lead Scholar Rock Holding's portfolio
Scholar Rock Holding has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Fibrosis related patents lead Scholar Rock Holding portfolio followed by cell therapy, and diabetes
Scholar Rock Holding has highest number of patents in fibrosis followed by cell therapy, diabetes, atrophy, and muscle atrophy.
For comprehensive analysis of Scholar Rock Holding's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.